A new study presents a pharmacological inhibitor targeting METTL1, an enzyme that modifies RNA, and reports that blocking its activity suppresses growth in both solid tumour and blood cancer models. The paper also describes the biochemical methods used, including expression and purification of the full-length METTL1–WDR4 protein complex, to support structural and functional characterization of the drug target.
nature.com
· 2026-10-28
Researchers report that a cell-cycle regulating enzyme performs an additional, previously unrecognized function beyond its known role in cell division. The team suggests this extra function may help account for the toxic side effects observed when drugs that inhibit this enzyme are used in treatment.
nature.com
· 2026-10-28
Legend Biotech has appointed Ingrid Zhang, an executive from Novartis, as its new chief executive officer. She fills a leadership vacancy that opened in July after the company's previous CEO resigned abruptly.
wsj.com
· 2026-09-15
As Moderna and Merck develop personalized cancer therapies, data and diagnostics firm Tempus AI is emerging as a key infrastructure player supporting that work. Personalis, a genomic testing company, sits at the center of this positioning, suggesting a broader supply-chain opportunity beyond the drugmakers themselves.
wsj.com
· 2026-09-04
GoKawiil